Abstract
BackgroundImmune-checkpoint blockade (ICB) therapies have transformed the treatment landscapes of hepatocellular carcinoma (HCC). Despite unprecedented success in clinical trials, the immunosuppressive tumor microenvironment (TME) constructed by tumor cells restricts the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have